

The experience with suramin in advanced prostate cancer

Cancer

75, 1927-1934

DOI: [10.1002/1097-0142\(19950401\)75:7+<1927::aid-cnrcr2820751628>3.0.co;2-a](https://doi.org/10.1002/1097-0142(19950401)75:7+<1927::aid-cnrcr2820751628>3.0.co;2-a)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D3 on prostatic epithelial cells. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995, 1, 188-194.	0.8	14
3	Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.. <i>Endocrine-Related Cancer</i> , 1999, 6, 373-387.	1.6	133
4	Phase II study of vinorelbine in patients with androgen-independent prostate cancer. <i>Annals of Oncology</i> , 2001, 12, 847-852.	0.6	39
5	Phase I Drug Interaction Study of Suramin and Warfarin in Patients With Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 167-171.	0.6	6
6	The management of prostate cancer in patients with a rising prostate-specific antigen level. <i>BJU International</i> , 2001, 86, 181-190.	1.3	7
9	The management of prostate cancer in patients with a rising prostate-specific antigen level. <i>BJU International</i> , 2008, 86, ii-iii.	1.3	6
10	Treatment of Metastatic Carcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 40-45.	0.6	14